Cell MedX Corp. (OTC:CMXC) had uplifting news Tuesday. The early development-stage biotech company, based in Carson City, Nevada, and focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced significant progress toward obtaining pre-market clearance in the U.S. for its eBalance device.
The eBalance device is not yet available for sale in the U.S.
The Company has been working with ICON plc to assemble the necessary documentation to support the 510(k) pre-market notification for the eBalance device with a goal to obtain pre-market clearance and make the medical device available to the U.S. market. The Company anticipates filing the application in the first quarter of 2019.
Cell MedX directs its efforts at alleviating complications associated with medical conditions such as diabetes, Parkinson's disease, and high blood pressure
Shares in CMXC jumped seven cents, or nearly 54%, to 20 cents, despite underwhelming volume of 10,000 shares.
